Mucosa-associated lymphoid tissue (MALT)
lymphoma, 399
Multidrug resistant (MDR) isolates, 512
Multidrug resistant (MDR) pathogens
Acinetobacter baumannii, 222
Multidrug-resistant (MDR) TB, 157, 326–327
Multiple fever spikes, 8
Multiple sclerosis (MS), 92, 93, 377
natalizumab for, 379, 382
Mupirocin, 109, 362
Murmur
apical diastolic.SeeApical diastolic murmur,
physical findings
apical pan-systolic.SeeApical pan-systolic
murmur, physical findings
basilar diastolic blowing.SeeBasilar
diastolic blowing murmur, physical
findings
pan-systolic.SeePan-systolic murmur, physical
findings
Murray Valley encephalitis, 329
Musculoskeletal adverse reactions, 549
Mutton fat keratic precipitates in fundi, 72
MVP.SeeMitral valve prolapse (MVP)
MW2 strain, of CA-MRSA, 103
Mycobacterium, 310
Mycobacterium avium, 380
Mycobacterium leprae, 380
Mycobacterium marinum, 380, 479
skin infections and, 300
Mycobacterium tuberculosis (TB), 67, 156
in SOT recipients, 393–394
Mycophenolate, 377
Mycophenolate mofetil, 387, 391, 399, 400, 404
Mycoplasma hominis, 398
Mycoplasma pneumonia, 159
Mycoplasma pneumoniae, 170, 345, 425
Mycotic aortic aneurysms, 423
Myocardial infarction (MI)
CAP and, 165
Myoglobinuria, 307
Nafcillin plus gentamicin
for MSSA/MRSA ABE, 211
Nasal discharge, physical findings
diagnostic features, 52
noninfectious mimics, 52
Nasal septal perforation, physical findings
diagnostic features, 53
noninfectious mimics, 53
Natalizumab
for Crohn’s disease, 382
for multiple sclerosis, 379, 382
National Nosocomial Infection Surveillance (NNIS)
System, 178, 310
Native valve IE (NVIE), 223, 227, 228, 238.See also
Infective endocarditis (IE)
organ involvement in, 230
NBTE.SeeNonbacterial thrombotic endocarditis
(NBTE)
Necrotizing fasciitis (NF), 301
antimicrobial therapy and microbiology
associated with, 306
clinical features, 303
diagnosis, 303–304
treatment, 304–305
Necrotizing soft tissue infections
cellulitis, 302
Fournier’s gangrene, 305
gas gangrene, 305–307
necrotizing fasciitis (NF), 302–305
nonclostridial myonecrosis, 307–308
Neisseria meningitidis, 19, 144, 352
Neonatal intensive care unit (NICU)
CA-MRSA infections, 104
decolonization of patients in, 110
HA-MRSA
epidemiology of, 106
infections, 104
sites of infections caused by noscomial
MRSA in, 104
VRE
risk factors for acquisition of, in, 114
type of infection caused by, in, 113
Neoplastic diseases, 427
Nephrectomy, 76
Nephrotoxicity, 544
Neuro-Behc ̧et’s disease, 138
Neurocysticercosis, 402
Neuroimaging
meningitis and, 148
Neurological focality
in SOT recipients, 400–402
Neuropathogenic bacteria, 134, 143
Neuropathy, 308
symptoms, 160
Neurosarcoidosis, 138
Neurosyphilis, 158
Neutropenia, 310
NF.SeeNecrotizing fasciitis (NF)
NICU.SeeNeonatal intensive care unit (NICU)
Nikolsky sign, skin, 35
Nipah virus encephalitis, 329
N-methylthiotetrazole, 547
NNIS.SeeNational Nosocomial Infection
Surveillance (NNIS) System
Nocardia cerebritis, 86
Nocardia farcinica, 394
Nocardiaspp., 380, 402
infection, in SOT recipients, 392, 394
Nocardiosis, 402
Nodular rashes
erythema nodosum, 40
rheumatic fever, 41
systemic fungal infections, 40–41
Nonantibiotic therapy, of IE, 238–240
Nonbacterial thrombotic endocarditis
(NBTE), 224
Nonb-lactam antibiotics
in patients with penicillin anaphylactic reactions,
537–539572 Index